Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
An investigational fecal microbiota transplant (FMT) therapy being studied for the treatment of rheumatoid arthritis. Developed by Lawson Health Research Institute (the research institute of London Health Sciences Centre and St. Joseph's Health Care London), this therapy consists of oral capsules containing processed fecal microbiota from screened healthy donors. The modality is a live biotherapeutic product intended to modify the gut microbiome. The presumed mechanism of action involves restoring a healthy composition of gut bacteria, which may in turn modulate the immune system and reduce autoimmune activity. It is being evaluated in a randomized, double-blind, placebo-controlled proof-of-concept study known as the FeMiTRA01 trial (NCT05790356) in patients with rheumatoid arthritis.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on fecal microbiota transplant (Lawson Health Research Institute).